Company Overview
Snapshot
Founded in April 2021 by Shmuel Mandel, PsygaBio operates with 1–10 employees. The company has secured funding across one round from NFX Capital. PsygaBio is focused on drug discovery, leveraging natural compounds for therapeutic development.
Business overview
PsygaBio is a drug discovery company specializing in developing therapeutics derived from natural compounds. Utilizing Cannasoul's proprietary analytical platform, PsygaBio employs a data-driven approach, expertise, and a clinical trial framework to identify and develop active compounds. This process spans from mushroom cultivation and extraction to clinically approved formulations. In partnership with Cannasoul Analytics, PsygaBio aims to explore the diversity of psychedelic mushrooms to identify active compounds and formulations for therapeutic benefits, operating within the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- Who founded PsygaBio?
- PsygaBio was co-founded by Shmuel Mandel.
- When was PsygaBio founded?
- PsygaBio was founded in April 2021.
- What is PsygaBio's primary focus?
- PsygaBio is a drug discovery company focused on developing therapeutics derived from natural compounds, particularly from psychedelic mushrooms.
- What is PsygaBio's relationship with Cannasoul Analytics?
- PsygaBio is a subsidiary of Cannasoul Analytics and partners with them to use their proprietary analytical platform for identifying active compounds and formulations.
- What is PsygaBio's current product stage?
- PsygaBio is currently in the R&D product stage, focusing on identifying active compounds and formulations from psychedelic mushrooms for therapeutic benefits.